Founded in 2000 as a spin-off from the Medical University of Innsbruck, Vitateq Biotechnology focuses on the function of the vitamin E-binding protein AFAMIN. Their research explores the diagnostic and therapeutic applications of this biomarker in multiple health conditions, such as infertility disorders, cardio-vascular diseases, and neurodegenerative ailments. By utilizing proteomics and antibody-based protein quantification, the company aims to provide medical solutions that enable healthy pregnancy and improve the treatment of various diseases.